TEVA.N
Latest Trade
8.99USDChange
-0.02(-0.22%)Volume
788,227Today's Range
-
9.2752 Week Range
-
13.76As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 9.01 |
|---|---|
Open | 9.06 |
Volume | 788,227 |
3M AVG Volume | 185.22 |
Today's High | 9.27 |
Today's Low | 8.97 |
52 Week High | 13.76 |
52 Week Low | 6.25 |
Shares Out (MIL) | 1,095.78 |
Market Cap (MIL) | 9,864.69 |
Forward P/E | 3.53 |
Dividend (Yield %) | -- |
Collegium Announces Settlement With Teva Resolving Xtampza Er Patent Litigation
Alkermes Files Lawsuit Against Teva USA & Teva Pharmaceutical Industries
Teva Pharma Finance Netherlands Offering To Exchange Upto €1 Bln Of 6% Senior Notes
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Industry
Biotechnology & Drugs
Executive Leadership
Sol J. Barer
Independent Chairman of the Board
Kaare Schultz
President, Chief Executive Officer, Director
Eliyahu Sharon Kalif
Chief Financial Officer, Executive Vice President
Mark Sabag
Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
Richard Daniell
Executive Vice President - European Commercial
Price To Earnings (TTM) | 3,478.76 |
|---|---|
Price To Sales (TTM) | 0.60 |
Price To Book (MRQ) | 0.71 |
Price To Cash Flow (TTM) | 6.60 |
Total Debt To Equity (MRQ) | 189.61 |
LT Debt To Equity (MRQ) | 177.71 |
Return on Investment (TTM) | -0.33 |
Return on Equity (TTM) | -0.25 |
New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.
The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd on Tuesday with conspiring with competitors to raise prices for generic drugs.
U.S. prosecutors brought insider trading charges against the founder and former chief executive of Auspex Pharmaceuticals Inc, accusing him of providing illegal tips to friends and family as Teva Pharmaceutical Industries Ltd <TEVA.TA> prepared to buy his company in a $3.5...
U.S. prosecutors on Tuesday announced insider trading charges accusing the former chief executive of Auspex Pharmaceuticals Inc with tipping friends and family about an anticipated tender offer for his company by Teva Pharmaceutical Industries Ltd in 2015.
U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd with conspiring with competitors to raise prices for generic drugs, Bloomberg Law reported on Tuesday citing a person familiar with the matter.
New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.
New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.
The U.S. government sued Teva Pharmaceutical Industries Ltd <TEVA.TA> on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare by using kickbacks to boost sales of its multiple sclerosis drug Copaxone.
REUTERS - The U.S. government sued Teva Pharmaceutical Industries Ltd on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug Copaxone.
A Florida-based specialty pharmacy will pay $3.5 million to resolve allegations it served as a conduit for a Teva Pharmaceutical Industries Ltd subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said on Thursday.
Teva Pharmaceutical Industries' <TEVA.TA> quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis.
* TEVA PRESENTS NEW ANALYSES EXAMINING CHANGES IN MIGRAINE DISABILITY OUTCOME MEASUREMENTS WITH AJOVY® (FREMANEZUMAB-VFRM) INJECTION
* TEVA TO PRESENT NEW DATA ON AJOVY® (FREMANEZUMAB-VFRM) INJECTION OPEN-LABEL EXTENSION STUDY AT AMERICAN HEADACHE SOCIETY ANNUAL MEETING Source text for Eikon: Further company coverage:
* TEVA PHARMACEUTICAL INDUSTRIES - SHAREHOLDERS APPROVED AMENDMENT NO. 1 TO TERMS OF OFFICE AND EMPLOYMENT OF CO'S CEO KÅRE SCHULTZ AT ANNUAL MEETING
EU antitrust enforcers, boosted by recent court victories, on Monday reinforced their case against Israeli drugmaker Teva over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil.
* US FDA SAYS TEVA RECALLING 14 LOTS OF METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP 500 MG AND 750 MG, DUE TO DETECTION OF EXCESS NDMA LEVELS Source text : https://bit.ly/2zYnSAl Further company coverage:
Teva Pharmaceutical said on Monday that China has given the go-ahead to its Austedo treatment for Huntington's disease.
China has given the greenlight to Teva Pharmaceutical Industries' <TEVA.N> Austedo treatment for Huntington's disease, the company said on Monday.
* Shares jump almost 20% (Adds CEO comments on migraine drug, contract extension)
* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.